Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
TrkA receptor antagonist
DRUG CLASS:
TrkA receptor antagonist
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
AB-106 (5)
K-252a (1)
VMD-928 (0)
TZLS-201 (0)
AB-106 (5)
K-252a (1)
VMD-928 (0)
TZLS-201 (0)
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
AB-106
Sensitive: B - Late Trials
AB-106
Sensitive
:
B
AB-106
Sensitive: B - Late Trials
AB-106
Sensitive
:
B
CD74-ROS1 fusion
Non Small Cell Lung Cancer
CD74-ROS1 fusion
Non Small Cell Lung Cancer
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
AB-106
Sensitive: C3 – Early Trials
AB-106
Sensitive
:
C3
AB-106
Sensitive: C3 – Early Trials
AB-106
Sensitive
:
C3
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
AB-106
Sensitive: C4 – Case Studies
AB-106
Sensitive
:
C4
AB-106
Sensitive: C4 – Case Studies
AB-106
Sensitive
:
C4
FLT3 G697R
Acute Myelogenous Leukemia
FLT3 G697R
Acute Myelogenous Leukemia
K-252a
Sensitive: D – Preclinical
K-252a
Sensitive
:
D
K-252a
Sensitive: D – Preclinical
K-252a
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login